Myeloma Clinical Trial - Bendamustine in Combination With Lenalidomide &

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03832127` - Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients	Phase 1
Completed	`NCT01413178` - A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma	Phase 3
Recruiting	`NCT03641456` - VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma	Phase 2
Terminated	`NCT02907073` - Positron Emission Tomography (PET) Imaging Studies With NIS Reporter	Phase 1/Phase 2
Completed	`NCT03135925` - Feasibility of Pre Transplant Exercise (Pre-habilitation) for Multiple Myeloma Patients Awaiting Autologous Stem Cell Transplantation	N/A
Withdrawn	`NCT02114502` - Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma	Phase 2
Completed	`NCT00800839` - Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide	Phase 2
Completed	`NCT01700608` - Prospective Observational Study on Plerixafor After Chemotherapy	N/A
Completed	`NCT00794261` - Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma	Phase 2
Completed	`NCT00606437` - Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants	Phase 1
Recruiting	`NCT05528887` - Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies	Phase 1
Recruiting	`NCT05625971` - Non-invasive MRD Assessment in Multiple Myeloma
Active, not recruiting	`NCT02931942` - Changing Over Time of Ascorbic Acid After Chemotherapy
Active, not recruiting	`NCT05889221` - Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma	N/A
Recruiting	`NCT03836690` - Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation	Phase 1
Active, not recruiting	`NCT02542657` - Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma	Phase 1/Phase 2
Completed	`NCT01191060` - Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years	Phase 3
Completed	`NCT01279694` - Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)	Phase 1/Phase 2
Terminated	`NCT00983346` - Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients	Phase 2
Completed	`NCT00476294` - Long-Term Follow Up Study for AMD3100 Patients	N/A

NCT number	NCT01042704
Study type	Interventional
Source	University of Pittsburgh
Contact
Status	Completed
Phase	Phase 1
Start date	February 2008
Completion date	March 2015

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms